Clinical research organization ICON plc (NASDAQ:ICLR) stock is surging on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2025 sales ...
ICON may be relatively undervalued, trading at a ~10% discount to IQVIA and offering an attractive ~7% free cash flow yield that markets seem to be responding to now. The CRO sector faces near-term ...
The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Icon ( (ICLR)) has issued an announcement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback